Pfizer's Xeljanz wins nods in Switzerland, Russia; Actavis gets FDA blessing for copy of Endo painkiller;

 @FiercePharma: AstraZeneca CFO jumps ship in latest executive switcheroo. News | Follow @FiercePharma

 @EricPFierce:  Novartis CEO Jimenez says China is a difficult market, but worth it. I wonder if GSK agrees right now. Article | Follow @EricPFierce

 @CarlyHFierce: Here's Vivus' release re: delaying its shareholder meeting - says First Manhattan made false statements. Release | Follow @CarlyHFierce

> Pfizer's ($PFE) new rheumatoid arthritis treatment Xeljanz won approval in several more countries, including Switzerland, Argentina and Russia. Release

> Actavis ($ACT) won FDA approval for its version of the Endo Health Solutions painkiller Opana ER, while the two companies are locked in a patent fight over a couple of dosage strengths. Release

> India's Export-Import Bank said it would offer long-term financing to Indian drugmakers to help them establish manufacturing plants that meet the FDA's standards. Report

> Belgium's UCB sued Mylan ($MYL) for patent infringement after the generic drugmaker asked the FDA to approve its versions of the seizure drug Vimpat. Report

> Swiss regulators green-lighted a new indication for Eisai's epilepsy drug Zonegran. Report

Medical Device News

 @FierceMedDev: AngioDynamics' FY 2013 reflects a partial upswing. Story | Follow @FierceMedDev

 @MarkHFierce: Give us your FMD Fierce 15 nominations today - Device and Dx nominations welcome. Submit here | Follow @MarkHFierce

 @DamianFierce: AstraZeneca signs up with genomics outfit Blackfield for cancer R&D. More | Follow @DamianFierce

> J&J smacked with Canadian lawsuit claiming vaginal mesh implant damage. News

> Given Imaging's PillCam Colon capsule wins Japanese approval. Report

> FDA hits Medtronic with Class I recall over faulty insulin pump part. Story

Biotech News

 @FierceBiotech: ICYMI last week: The biotech IPO scene turns red hot. Special report | Follow @FierceBiotech

 @JohnCFierce:  Vivus pushes back shareholder meeting, a sure sign they are losing the fight with FMC. Report | Follow @JohnCFierce

 @RyanMFierce: Europe eyes social media and mobile for data on bad drug reactions. Story | Follow @RyanMFierce

 @EmilyMFierce: You can't patent human genes. So why are genetic testing companies getting sued? Article | Follow @EmilyMFierce

> Is this the NIH Francis Collins wanted to create? Editor's corner

> Ipsen bags a development platform with $207M Syntaxin buyout. Story

> Buzz: Why is Roche considering a big buyout of Alexion? Report

> Merck's positive Alzheimer's study spotlights BACE race. More

CRO News

> Corgenix signs CMO deal with EDP Biotech. Item

> Theorem, Emergo team up for devices and diagnostics. News

> NIH, industry back out of India as trials slow to standstill. Article

> Catalent inks Biota flu deal, shifts delivery biz. Story

Biotech IT News

> Europe eyes social media and mobile for data on bad drug reactions. News

> High-profile VC Sequoia backs clinical tech startup Comprehend in $8.4M round. Story

> Boehringer Ingelheim expands use of Big Data tech for pharma research. Article

> ChemAxon extends pharma software streak with Schrödinger deal. Item

And Finally... Brazil's plan to hire doctors from abroad won't address problems with state healthcare such as supply shortages, local physicians said. Report

Suggested Articles

Long-time trend watcher and marketer Rohit Bhargava challenged pharma marketers to adopt new habits to become non-obvious thinkers.

Samsung Biologics opened the doors to its first-ever US CDO R&D Center in San Francisco.

When the COVID-19 pandemic began, early fears of shortages of pharmaceutical supplies and drugs were quickly abated by a responsive supply chain.